An interventional study of Qualia Iron Version A and Qualia Iron Version B in Iron Deficiencies, sponsored by Qualia Life Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Qualia Life Sciences · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Iron Deficiencies with a site in United States — 16 open to participants now, 20 under way, 4 of them phase 3. Iron Deficiencies · United States.
Among the 82 studies in Iron Deficiencies with a site in United States, this one is the 45th largest by planned enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2026, is one of 29 with no phase, reaches primary completion later than 3 of the 19 other live ones, and was the 72nd registered.
386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.
Browse Iron Deficiencies studies →16 of the 82 studies in Iron Deficiencies with a site in United States are open now. Recruiting first, the newest first:
Lindenwood University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Kaiser Permanente · Sites in United States
Ages 18+
Pennington Biomedical Research Center · Sites in United States
Ages 18–50 · Healthy volunteers
University of Illinois Chicago · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Columbia University · Sites in United States
Ages 10–19
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 14 · Phase 4 10
First in 2000; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 89 across the 63 interventional studies, 73 across the 18 observational. Of the 57 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 82 have an industry lead sponsor. The 10 most frequent:
Qualia Life Sciences is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Qualia Life Sciences has 1 study filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
10 of the studies in Iron Deficiencies with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179226Phase 3Pharmacosmos A/SMulti-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia | 2027-04-30 |
| NCT07217873Phase 3Columbia UniversityIntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study | 2027-08-31 |
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT07892911Ancestral Supplements, LLCA Study to Evaluate the Effects of a Beef Liver Supplement on Energy, Mood, and Mental Clarity | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 82 studies in Iron Deficiencies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This double-blind parallel pilot study will evaluate the safety and efficacy of two Qualia Iron formulations versus placebo in approximately 40 healthy adults (aged 18+) over a 56-day period. Approximately 40 participants will be assigned to three study arms: Qualia Iron Version 1, 2, (n=15 each) or a Placebo (n=10). Each participant will take one or two capsules once daily in the morning, with or without food. The supplementation regimen is a 5 days on, 2 days off protocol, and goes for 56 days (8 weeks). The primary outcomes of this study are to assess between-group changes in iron status biomarkers. Secondary outcomes include within-group changes in iron status biomarkers, safety and tolerability as measured by a custom Safety and Tolerability survey, and RAND SF-36 quality of life scores.
Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. No other aspect of the study design, conduct, or analysis changed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ferritin 30 ng/mL (anything under 50 ng/mL is considered suboptimal, but participants with 30 ng/mL will be prioritized)
Exclusion Criteria:
Antacids Proton pump inhibitors (PPIs) Antipsychotics Antibiotics
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Qualia Iron version A manufactured by Qualia Life Sciences
Dietary Supplement: Qualia Iron Version A
Qualia Iron version B manufactured by Qualia Life Sciences
Dietary Supplement: Qualia Iron Version B
Rice powder
Dietary Supplement: Placebo
Qualia Iron Version A manufactured by Qualia Life Sciences
Qualia Iron Version B manufactured by Qualia Life Sciences
Rice powder
Changes in iron status biomarkers
Between-groups changes in ferritin levels (ng/mL) will be assessed.
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in iron status biomarkers
Changes in serum iron (mcg/dL)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in iron status biomarkers
Changes in percent saturation (%)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in iron status biomarkers
Changes in total iron binding capacity (mcg/dL)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in CBC markers
Changes in hematocrit (%)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in CBC markers
Changes in hemoglobin (g/dL)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in CBC markers
Changes in red cell distribution width (%)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in CBC markers
Changes in mean corpuscular volume (fL)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in CBC markers
Changes in mean corpuscular hemoglobin (pg)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in CBC markers
Changes in mean corpuscular hemoglobin concentration (g/dL)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in CBC markers
Changes in red blood cell count (million/microliter)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in RAND 36-Item Short Form Survey (SF-36)
The RAND SF-36 captures 8 separate aspects of health-related quality of life using the same 0-to-100 scoring scale for all eight domains. Higher scores represent better health outcomes.
Time frame: From 0-4 weeks, 4-8 weeks, 0-8 weeks
Changes in Safety and Tolerability measured by Custom Survey
Changes in safety and tolerability measures will be examined in each group using a custom survey. The survey asks about common nocibo side effects, including increasing anxiety/worry, headache, mood changes, stomach upset/nausea, dizziness, bloating, itching, and sexual function. The scoring system goes from "not at all" to "a great deal" for each item, . The total score for each category across all participants will be calculated, and then timepoint comparisons will be made.
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in inflammatory markers
Changes in high sensitivity C-reactive protein (mg/L)
Time frame: From 0-4 weeks, 4-8 weeks, and 0-8 weeks
Changes in iron status biomarkers
Within-groups changes in ferritin (ng/mL) will be assessed.
Time frame: From 0-4 weeks, 4-8 weeks and 0-8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 88 interventional studies with no phase under Iron Deficiencies, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 6 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Sep 2025 → Jun 2026, primary completion Nov 2025 → Dec 2026 and completion Nov 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.